Serratia Bacteraemia in the North Denmark Region: A Population-Based Study (2010-2024)
Abstract
Population-based data on Serratia bacteraemia are limited. We conducted a population-based cohort study of patients with a first-time episode of Serratia bacteraemia in the North Denmark Region between 1 January 2010 and 30 June 2024 (catchment population ~590,000). Clinical and microbiological data were obtained from medical records and the regional microbiological database. A total of 188 patients were identified. The median age was 70 years (IQR 60-78), 66% were male and 48% had a high Charlson Comorbidity Index score (≥ 3). The annual incidence remained stable at 2.1 per 100,000 person-years (95% CI 1.8-2.5). Bacteraemia was community-acquired in 38% of patients, healthcare-associated in 2% and hospital-acquired in 37%. The most common foci of infection were the urinary tract (25%), hepatobiliary tract (20%) and respiratory tract (14%), while a focus was not identified in 28% of patients. Thirty-day all-cause mortality was 24%. In an exploratory adjusted Poisson regression analysis, increasing age (RR 1.02, 95% CI 1.00-1.05) and high comorbidity (RR 2.58, 95% CI 1.01-6.63) were associated with increased mortality, whereas acquisition was not. Serratia bacteraemia predominantly affected older patients with substantial comorbidity and was associated with considerable mortality. Host-related factors appeared to be important determinants of outcome.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 188 participants or records.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.